Vilacto Bio Inc. Retains Established Independent Investor Relations Firm, The Equity Group Inc.

Vilacto Bio Inc. Retains Established Independent Investor Relations Firm, The Equity Group Inc.

COPENHAGEN, Denmark, Nov. 17, 2017 (GLOBE NEWSWIRE) -- Vilacto Bio Inc. (OTCQB:VIBI), today announced that it has retained The Equity Group Inc. to facilitate all aspects of the Company's investor relations and financial communications.

Vilacto Bio selected The Equity Group due to its 43-year track record of delivering specialized, comprehensive IR programs for small- and mid-sized public companies.  The Equity Group combines legacy knowledge of capital markets communications, and an unparalleled reputation for integrity and client service with evolving industry best practices to design and execute investor relations programs that help deliver long-term shareholder value.

?Vilacto Bio seeks to establish associations with only organizations of the highest caliber and we have again demonstrated this by engaging The Equity Group,? stated Gert Andersen, CEO of Vilacto Bio. ?We are confident in their ability to help us provide professional corporate communications and investor relations to all stakeholders of Vilacto Bio."

About The Equity Group

Founded in 1974 and headquartered in New York City, The Equity Group helped launch the practice of investor relations and financial communications.  Now in its fifth decade as an independent, full-service investor relations firm, the firm is led by a seasoned team of professionals with over 175 years of aggregate experience.  Learn more at www.theequitygroup.com.

About Vilacto Bio Inc.:

Vilacto Bio Inc. (OTCQB:VIBI) is a cosmeceutical and biotech company that has exclusive rights to the fully patented Lactoactive^® molecule, which in numerous studies has demonstrated above average effect in treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. The Company also developed and markets a consumer skincare line under the Vilact^® trademark.  The Company aims to further develop its Lactoactive^® molecule for the purpose of increasing the quality of its retail and medical skin cream products as well as licensing its Lactoactive^® molecule to the pharmaceutical industry.

Vilacto Bio Inc.
Fabriksvej 48
4700 Naestved
Denmark

Gert Andersen
Phone: +1 646-893-7895
[email protected]
www.vilactobio.com     

Forward-Looking Statements & Disclaimers:

The information in this Press Release includes certain "forward-looking" statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.